Key points {#Sec1}
==========

It is hypothesised that cell death by cryoablation leaves the intracellular contents of the cancer cells intact for the immune system to induce an immune-specific reaction also known as the abscopal effect.Immunotherapy uses the immune system for treatment of the tumour, but not all patients respond to immunotherapy.Combination of cryoablation with immunotherapy may enhance the effect of both therapies for better tumour destruction.

Introduction {#Sec2}
============

Cryoablation is a percutaneous ablation technique that uses extreme low temperatures for tumour destruction \[[@CR1]\]. During cryoablation liquefied gas, such as nitrogen or argon, is passed through cryoprobes and expands into a gaseous state at the end of the probe to create temperatures as low as − 190 °C. Cytotoxic cell destruction is achieved at temperatures below − 20 °C. To ensure complete ablation of the tumour, a circumferential margin of 1 cm is needed \[[@CR2]\]. After the freezing phase, a thawing phase follows by replacing the liquefied gas with helium or internally heating the needle (available in new systems). The whole process of freezing-thawing is repeated to obtain an effective ablation. Intra-procedure computed tomography (CT) identifies the ablated zone in real time as a low-density area which corresponds to the generated ice ball (Fig. [1](#Fig1){ref-type="fig"}). The procedure results in focal destruction of tumour tissue in a minimal invasive setting with reduced morbidity and mortality and represents a cost-effective alternative to surgery \[[@CR3], [@CR4]\]. However, surgery remains the gold standard in most tumour types with additional pathological assessment of margins \[[@CR5], [@CR6]\]. A possible advantage of cryoablation is that the intracellular contents of the damaged tumour cells are preserved and can be recognised by the immune system initiating a tumour-specific immune response (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR7], [@CR8]\]. Recently, immune checkpoint inhibitors have been studied for treatment of melanoma, renal cell carcinoma (RCC) and non-small lung cancer (NSLC). The challenge of the immune checkpoint inhibitors is that only a minority of patients respond. Therefore, a combination treatment of cryoablation and immunotherapy, might be beneficial to enhance the effect of the immune checkpoint inhibitors (Fig. [3](#Fig3){ref-type="fig"}).Fig. 1Cryoablation of a patient with stage IA renal cell carcinoma. The hypodense area around the needle corresponds with the generated ice ball in real timeFig. 2One of the hypotheses of how cryoablation induces an immune response is in the way cell death is induced. Cryoablation induces cell death by both necrosis and apoptosis. Necrosis releases intra-cellular contents stimulating signals (among others danger signals) that may activate T cells for a specific immune response to the cryoablated tissue. Contrary, after cell death by apoptosis, only apoptotic bodies are released, without stimulating signals. Without these stimulating signals, T cells are not being activated. Therefore, apoptosis may lead to an immune-suppressing signalFig. 3For T cell activation, both stimulatory signal 1 and 2 are needed. Signal 1 consists of the interaction between the major histocompatibility complex on the dendritic cell and the T cell receptor. Different combinations of interactions are possible for signal 2. One inhibiting signal 2 is the interaction between programmed death receptor 1 (PD-1) on T cell and programmed death ligand 1 (PD-L1) on tumour cells or antigen presenting cells. **a** T cell activation is blocked by an inhibiting signal 2 between PD-L1 and PD-1 receptor binding. **b** When an anti-PD1 antibody is used, the inhibiting signal of the T cell is blocked whereby an activation signal of the T cell is gathered and the T cell is activated

In the early 1970s, Shulman et al. reported the production of antibodies specifically against cryoablated tissue in rabbits \[[@CR9], [@CR10]\]. This immunogenic effect potentially resulted in a "bystander effect" with regression of tumours outside the primary ablation zone, known as the abscopal effect, firstly defined by Mole after radiotherapy \[[@CR11], [@CR12]\]. Unfortunately, this effect occurs infrequently, but when cryoablation is combined with other immunomodulatory therapy, this effect might be enhanced (Fig. [3](#Fig3){ref-type="fig"}) \[[@CR13]\]. Here, we review the current evidence on the combination of cryoablation with immunomodulatory drugs (immunotherapy).

Material and method {#Sec3}
===================

A literature search in MEDLINE was performed for available publications between 2001 and 2017 about cryoablation, its effect on the immune system and the combination of cryoablation and immunotherapy. Only full text articles available in English were included. Keywords included cryoablation, immune system, immunotherapy, melanoma and cancer. Data collection included factors related to the synergy between cryoablation and the immune system, cryoablation and immunotherapy, effect of cryoablation on tumour tissue and cryoablation technique. For immunotherapy, all therapies which could theoretically enhance the anti-cancer immune response through either stimulation of the adaptive or innate immune system were included. Studies could be performed in patients and animals. Articles about combination of different ablation modalities were excluded.

A total of 45 relevant papers were identified and the most interesting and relevant studies were used for this review. To outline this paper, the studies were structured by tumour type and the current knowledge about the tumour type, cryoablation and immunotherapy was reviewed.

Results {#Sec4}
=======

Cryoablation and the immune system {#Sec5}
----------------------------------

Cryoablation may be synergistic with the immune system in the way cell death is induced. After ablation, the tumour remains, releasing various factors attracting the immune system. A proposed theory regarding the potential mechanisms of cryoablation and the immune system is the danger theory of Matzinger \[[@CR14], [@CR15]\]. This theory proposes that after cell death by necrosis, cells secrete danger signals. These danger signals can initiate an immune response. In addition, these signals can mature dendritic cells (DCs) to fully activate T cells which may lead to a specific immune response. Cryoablation induces cell death by necrosis in which intracellular contents are still preserved while DNA, RNA and heat shock protein (HSP), which can induce danger signals, are released \[[@CR16]\]. On the other hand, the cells in the outer margin of cryoablated tissue die from apoptosis and do not release DNA, RNA and HSP, and with no danger signal, the DCs remain immature. Immature DCs may trigger immune suppressive signals that could lead to anergy (T cell inactivation) \[[@CR17], [@CR18]\]. Therefore, cryoablation can induce both an immunostimulatory and immunosuppressive response (Fig. [2](#Fig2){ref-type="fig"}).

In addition, cytokines are produced after cryoablation, and these can also influence an immune response. Again, both immunosuppressive and immunostimulatory cytokines may be released depending on the tumour tissue, age and freeze rate \[[@CR19]\]. For cryoablation of liver tumours, when more than 20% of the liver volume is ablated, a systemic inflammatory response can occur due to a release of cytokines interleukine-6 (IL-6), IL-10 and tumour necrosis factor alpha (TNFα), which can have marked systemic effects \[[@CR7], [@CR20]--[@CR22]\]. Therefore, cryoablation is not the preferred treatment since heat-based ablations are better established in this setting \[[@CR23]\]. Yet, two clinical studies reported favourable outcomes on overall survival when cryoablation was combined with immunotherapy of allogenic natural killer (NK) cell infusion and dendritic cell cytokine-induced killer (DC-CIK) cells \[[@CR24], [@CR25]\].

Preclinical work from den Brok et al. confirms the effect of cryoablation on the immune system. This study reported that cryoablation creates an antigen depot resulting in maturation of DCs. The maturation of DCs led to a tumour-specific immune response protecting half of the mice against a new injection of similar tumour cells. When cryoablation was combined with an immune checkpoint inhibitor, anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4) antibody, this anti-tumour effect was further enhanced with up to 80% of the mice becoming tumour free \[[@CR26]\].

Clinical work by Takaki et al. evaluated peripheral blood after heath- and cold-based ablation modalities with pre-treatment (baseline) in different tumours showing no change in T cell subtypes (regulatory T cell (Tregs), T1 helper or Th2 helper cells) in all modalities, an elevation of cytotoxic T cells after heat-based ablative treatment was noted, and this was not identified after cryoablation \[[@CR27]\]. In a group of hepatitis B-positive hepatocellular carcinoma patients, the presence of elevated programmed cell death protein 1 (PD-1) on T cells and programmed cell death ligand 1 (PD-L1) expression on tumour cells had a poor overall survival post cryoablation \[[@CR28]\]. Theoretically, when combining cryoablation with a PD-1 inhibitor, such as nivolumab or pembrolizumab, the cryoablation induced adaptive immune resistance with upregulation of PD-L1 on tumour cells could be overcome, resulting in an effective anti-tumour T cell response. This potential synergy between cryoablation and anti-PD-1 may result in a more effective disease control; see Fig. [3](#Fig3){ref-type="fig"} \[[@CR29]\].

To enhance the immunogenicity effect of the cryoablation, different immunotherapies can be given as shown in Table [1](#Tab1){ref-type="table"}. Most immunotherapy enhances the innate immunity, namely natural killer (NK) cell therapy, dendritic cells (DCs) and CpG oligonucleotide (CpG ODN). When cryoablation presents the contents of the tumour cells, the innate immune system can assimilate these contents and present it to T cells; an immune response specific to the tumour cells could be obtained. Table [2](#Tab2){ref-type="table"} is an overview exhibiting the most studied factors after cryoablation in the reviewed papers.Table 1Summary of the major therapies with their mode of action used in combination with cryoablation in the reviewed papers. All therapies stimulate the immune system in a way and in combination with cryoablation an enhancement of this effect is hypothesizedTherapyMode of actionNumber of articlesCpG oligonucleotide (CpG ODN)Is recognized by dendritic cells (DCs) and B cells. Activates T cells, natural killer (NK) cells, monocytes, neutrophils and plasma cell differentiation8Anti-cytotoxic T lymphocyte-associated protein 4 (anti CTLA-4)Blocks the inhibitory receptor (CTLA-4) on the T cell and therefore activates the T cell for a specific immune response6Immature dendritic cells (DCs)Phagocytosis of pathogens; antigen-presentation to other immune cells (among others T cells)4Natural killer (NK) cell therapyInfusion with autologous NK cells to directly destroy tumour cells4Dendritic cell- cytokine induced killer (DC-CIK)May act similarly to T cells or NK cells but is unrestricted to major histocompatibility complex3Granulocyte-macrophage colony-stimulating factor (GM-CSF)A protein that functions as a cytokine and stimulates stem cells and can induce an immune cascade3Anti-programmed death-ligand 1 (PDL-1)Blocks the receptor programmed death 1 on the tumour cell. This results in the activation of the T cell to induce a specific immune response1Table 2Overview of the most studied factors of cryoablation and the immune system in the reviewed papersMost studied factors of cryoablation and the immune systemMiceTotal of 28 articles Survival↑17/17 Rechallenge of primary tumour↑12/12 Reduction in distant metastasis↑10/10 Cytokine release↑16/17 IFN-y release↑16/17 TNFα release↑4/5 IL-4↑1/7 IL-10↑1/4 Th1/Th2 cytokine ratio↑10/0 CD4+ infiltration↑12/16 CD8+ infiltration↑14/19 Treg↓5/6 NK cells↑3/4HumanTotal of 17 articles Survival↑8/8 Quality of Life↑4/4 Cytokine release↑6/7 IFN-y release↑6/7 TNFβ release↑3/4 IL-10↓3/5 IL-4↓3/4 IL-2↑3/5 Th1/Th2 cytokine ratio↑5/0 CD4+ infiltration↑5/8 CD8+ infiltration↑5/8 Treg↓2/2 NK cells↑4/4

Breast Cancer {#Sec6}
-------------

Cryoablation was approved for the treatment of fibroadenomas for over a decade \[[@CR30]\]. In 2016, the American College of Surgeons Oncology Group (ACOSOG) alliance considered cryoablation as an effective treatment for unifocal ductal cancer, with a success rate of complete tumour ablation of 92% after correction for multifocal disease \[[@CR31]\]. Also, for the treatment of stage IV breast cancer, cryoablation is a safe and effective procedure to control the disease and debulks the tumour in the breast \[[@CR32]\].

Although antibodies are part of the treatment for human epidermal growth factor receptor 2 (HER2)-positive breast cancers, no active forms of immunotherapy such as immune checkpoint inhibitors are currently approved for breast cancer. Recently, the interim analysis of the Impassion 130 study with the combination of nab-paclitaxel plus atezolizumab revealed an impressive 10 months of improvement in overall survival compared with chemotherapy alone in PD-L1-positive triple negative metastatic breast cancers \[[@CR33]\]. Other immune checkpoint blocking antibodies, such anti-CTLA-4 antibody, are also under investigation \[[@CR34]\].

One of the first reports confirming the immunogenicity of cryoablation in breast cancer was in a mammary mouse model. After cryoablation or surgery, mice were re-challenged with tumour cells and only 16% of the cryoablated exhibited tumour development compared to 86% of the surgically treated mice \[[@CR35]\].

In a metastatic breast cancer mouse model, cryoablated mice treated with a high freeze rate (100% cryoablation cycle) showed an improvement in overall survival with significant reduction in the number of pulmonary metastasis compared to treatment with a low freeze rate (10% cryoablation cycle) or those treated with surgery \[[@CR19]\]. When cryoablation was combined with injection of CpG ODN (a single-strand DNA molecule that acts as a toll-like receptor (TLR) agonist to stimulate and mature DCs) in mice, less tumour recurrence and secondary tumour growth were seen after the re-challenge compared to the mice that received cryoablation alone or surgery \[[@CR36]\]. No significant difference was reported between CpG ODN alone or in combination with cryoablation groups, leaving the added role of cryoablation to CpG ODN injection undetermined regarding cytokine release and potential immune activation \[[@CR36]\].

Other studies have investigated the combination of cryoablation with an immune checkpoint inhibitor (ipilimumab) 7 days before mastectomy in a group of patients with early-stage breast cancer. The pilot study, including 19 patients, showed that this approach was a safe option without delaying the mastectomy \[[@CR37]\]. A post hoc analysis was performed to assess the possibility of T cell receptor sequencing as a biomarker for T cell response to cryoablation, where no specific T cell response was observed \[[@CR38]\]. Additionally, a phase II trial is ongoing where cryoablation in combined with ipilimumab and nivolumab before breast surgery in triple negative breast cancer patients after taxane-based neoadjuvant chemotherapy \[[@CR39]\].

In another study, recurrent HER2-positive breast cancer patients were treated with the combination of cryoablation, trastuzumab and natural killer (NK) cell therapy (intravenous infusion of allogenic NK cells). These patients displayed a significantly prolonged progression-free survival (PFS), significantly larger numbers of T cells and Th1 cytokines together with a significantly reduction in the number of circulation tumour cells in the peripheral blood compared to patients only treated with cryoablation alone or cryoablation and NK cell therapy. To note, PFS was not reached in the triple combination group, and the significantly prolonged PFS could be due to trastuzumab \[[@CR40]\]. Niu et al. evaluated the use of cryoablation in combination with immunotherapy of DC-CIK cells in metastatic breast cancer patients versus chemotherapy or cryoablation alone. The group of patients that received multiple cryoablations (several sites) in combination with immunotherapy displayed a significantly longer median overall survival compared to the other groups \[[@CR41]\].

Together, cryoablation before mastectomy is feasible and its combination with immunotherapy, consisting of NK cell therapy, DC-CIK or anti-CTLA-4 antibody, is safe and effective in different stages in breast cancer. These results encourage further investigation into the combination of cryoablation and immunotherapy for breast cancer patients. Two trials are currently open which combine cryoablation with immune checkpoint inhibitors (Table [3](#Tab3){ref-type="table"}) \[[@CR42], [@CR43]\].Table 3Overview of clinical trials of cryoablation and immunotherapyCancer typeTumour stageStudy phaseStudy designTherapyEnd pointsEnd dateCentreIdentifierBreast cancerEarly/resectable diseasePilotOpen label single armPre-operative ipilimumab + nivolumab + cryoablationSafety: number of adverse events, no secondary end points.June 2019Memorial Sloan Kettering Cancer Center, USANCT02833233Resectable diseaseIIProspective randomized parallel interventionalPeri-operative cryoablation, ipilimumab nivolumab vs pre-operative careDistant disease-free survival\*May 2021Cedars-Sinai Medical Center, USANTC03546686Renal cell carcinomaMetastatic diseaseIOpen label single armTremelimumab +/− cryoablation before surgeryObjective response rate by irRC\*March 2021MD Anderson, USANCT02626130Stage I--Prospective observational cohortImmune response of cryoablation vs RFA vs LPNImmune response: number of leucocytes in tissue samples post ablation.June 2019UC Irvine, USANCT03409224Prostate cancerLocalized diseaseBasic scienceOpen label single armImmune response profile after total cryotherapy, focal cryotherapy, SBRT and radical prostatectomyEvaluate change in blood cytokine profileSept 2019Winthrop University Hospital, USANCT03331367Metastatic diseaseIIOpen label single armPembrolizumab and cryosurgery in combination with short term androgen ablationProportion of men with PSA \< 0.6 ng/mL PD-1/PDL-1 expressionNov 2018Sidney Kimmel Comprehensive Cancer Center, USANCT02489357Stage I tm IIBIProspective randomized open label clinical trialGM-CSF after cryoablationChange in B cell, T cells and PSA levelsDec 2018University of Colorado Cancer Center, USANCT02250014Castration resistant disease with positive lymph nodesIOpen label single armCryoablation plus intratumoural immature dendritic cellsMaximum tolerated dose\*April 2019Haukeland University Hospital, NorwegianNCT02423928Lung cancerStage IVIIOpen label single armCore needle biopsy and cryoablation added to continued treatment with immune checkpoint inhibitorResponse by RECIST\*March 2025Massachusetts General Hospital, USANCT03290677MelanomaStage III tm IV cutaneous melanomaI + IIOpen label single armDendritic cell therapy after cryosurgery in combination with pembrolizumabResponse by RECISTClinical benefit\*Oct 2022Mayo Clinic, USANCT03325101Stage IV,HLA-A2 + no curative diseaseIOpen label single armRadiofrequency therapy + RFA/CA+ GM-CSF injectionLevel of immune response by heat shock protein and lymphocyteResponse by RECIST\*May 2018Mayo Clinic, USANCT00568763OtherMetastatic Colorectal cancerI/IIbOpen label single armCombining cryoablation with intra-lesional immunotherapy with AlloStim® with dose escalationSafety of increased frequency of dosing\*Tumour response RECIST and histopathologyHRQoLFeb 2018MD Anderson Medical Center, USANCT02380443NB this study was first designed in BCPalliative stetting of HCC or BTCI/IIOpen label single armTremelimumab and durvalumab + RFA/CA/TACEPFS\*Apr 2021National institutes of health clinical centre, USANCT02821754Palliative stetting of HCC or BTC stage B and CIClinical prospective non-randomisedTremelimumab + RFA/CA/SBRT/TACEResponse RateTime to tumour progressionOverall survival\*Dec 2018National Institutes of Health Clinical Center, USANCT01853618OtherNon-Hodgkin lymphomaI/IIOpen label single armIntratumoral DC therapy after cryosurgery and pembrolizumabMaximum tolerated dose\*Complete responsesDisease free survival rateDuration of responseOS, PFS, HRQoLFeb 2021Mayo Clinic, USANCT030353311. Oesophageal cancer,2. Tongue cancer,3. Ovarian cancer,4. Laryngeal cancer,5. Pharyngeal cancer,6. Cervical cancer7. Tumours in transplanted livers8. SarcomaI/IIOpen label single arm trialCryoablation and NK cell immunotherapyResponse, PFS, OS by RECIST\*Jul 2019Cancer Institute in Fuda Cancer Hospital, ChinaNCT02843581NCT02849379NCT02849353NCT02849314NCT02849327NCT02849340NCT02849015NCT028493661. Breast cancer,2. Liver cancer,3. Lung cancer,4. Gastric cancer,5. Colorectal cancer,6. Pancreatic cancer7. Kidney cancerIIProspective randomized triple arm studyActivated CIK cells + anti-bispecific antibody with or without cryoablation vs conventional therapyObjective response ratePFSTTP\*April 2021Fuda Cancer Hospital, ChinaNTC03524261NTC03484962NTC03501056NTC03554395NTC03524274NTC03509298NTC03540199*RECIST* response evaluation criteria in solid tumours, *irRC* immune-related response criteria, *PFS* progression-free survival, *OS* overall survival, *CR* complete response, *PR* partial response, *HRQoL* health-related quality of life, *DSS* disease specific survival, *LHRH agonist* luteinizing-hormone releasing-hormone agonist, *TTP* time tumour progression, *RFA* radiofrequency ablation, *CA* cryoablation, *SBRT* stereotactic body radiotherapy, *DC* dendritic cell, *CIK* cytokine-induced killer cells, *NK* natural killer, *TACE* transarterial chemo-embolisation, *GM-CSF* granulocyte-macrophage colony-stimulating factor, *LPN* laparoscopic partial nephrectomy, *PSA* prostate specific antigen, *PD-1* programmed cell death protein, *PDL-1* programmed cell death ligand\*Safety has been performed in all studies by number of adverse events

Renal cell carcinoma {#Sec7}
--------------------

In RCC, cryoablation is most frequently used to treat stage I cancer (ideally smaller than 4 cm taken as the largest diameter) in patients not eligible for surgical resection \[[@CR44], [@CR45]\]. With optimal patient selection, results similar to partial nephrectomy can be achieved \[[@CR46]\].

Immunotherapy for RCC has been used for quite some time, and nivolumab, a PD-1 inhibitor, is already approved for the treatment of RCC \[[@CR47], [@CR48]\].

Two animal studies showed the favourable effect of cryoablation in the microenvironment of RCC and in the kidney. The first study used two mice models, one with and one without injected RCC to observe an inflammatory immune response after cryoablation in the tumour or healthy kidney tissue. An infiltration of neutrophils, macrophages and CD4+ and CD8+ T cells was reported after cryoablation whereby no difference was observed after cryoablation of normal kidney tissue or tumour tissue \[[@CR49]\]. Another study compared cryoablation with surgery and showed decreased tumour growth after the re-challenge of the tumour cells with significantly more T cells in the peripheral blood after cryoablation \[[@CR50]\].

Kato et al. showed that in half of the patients with T1 RCC, a significant increase in T cell receptor (TCR) B CD3 clonotypes of T-cells in post ablation tissue and blood was seen with a low diversity (TCR clones were not evenly distributed anymore) \[[@CR51]\]. In another clinical study, two sessions of cryoablation of the pulmonary metastases, each combined with two Intratumoural injections of granulocyte-macrophage colony-stimulating factor (GM-CSF), resulted in higher levels of NK cells, Th1 cytokines and T and B cells in the peripheral blood compared to baseline \[[@CR52]\]. Lin et al. showed similar effects of allogeneic NK cell immunotherapy combined with cryoablation in 60 advanced RCC patients, and this treatment combination resulted in more tumour responses and decrease in Hounsfield units count than cryoablation on its own \[[@CR53]\].

To summarise, cryoablation of RCC elicits an immune response and can be safely combined with GM-CSF and NK cell therapy. Currently, one trial is ongoing investigating the synergy of cryoablation with anti-PD-1 therapy (tremelimumab), and another trial investigates the effect of ablation of the immune system \[[@CR54], [@CR55]\].

Prostate cancer {#Sec8}
---------------

Cryoablation is currently being used to treat stage I prostate cancer. Cryoablation could also be considered as salvage treatment for local recurrence after radiation therapy. Future perspectives in prostate cancer shift towards a more targeted therapy where cryoablation may have an important role in prostate cancer \[[@CR56]\].

Presently in prostate cancer, the only approved immunotherapy is sipuleucel-T (Provenge), a DC-based immunotherapy that sensitises dendritic cells with prostate antigens and is used as a therapeutic vaccine \[[@CR57]\]. Other immunotherapies evaluated have failed to show improvement in overall survival \[[@CR58]--[@CR60]\]. Current developments are focusing on immunotherapy for the subgroup with defects in DNA-repair mechanisms, which include microsatellite instability and breast cancer gene mutations.

Waitz et al. reported a regression in secondary tumour growth with infiltration of CD4+ and CD8+ T cells and lower counts of Tregs in mice treated by cryoablation and anti-CTLA-4 antibodies \[[@CR29]\]. Another study reported that the combination of cryoablation with anti-CTLA-4 antibodies reduced distant metastasis in mice together with a reduction in the number of Tregs; these were lowest on day 14 but returned to normal levels at day 21 \[[@CR61]\]. Recently, combination therapy of androgen deprivation plus anti-PD-1, anti-CLTA-4 or placebo with or without cryoablation demonstrated a delay in distant tumour growth and decreased mortality in mice in the trimodal therapy groups \[[@CR62]\].

Pre cryoablation tissue in high-risk Localised prostate cancer patients showed elevated numbers of Tregs compared to healthy volunteers. Numbers of Tregs decreased significantly after cryoablation in the prostate patients, and, conversely, 7 of 12 patients had an increase of suppressive function of Tregs measured by immunosuppressive assay of CD4^+^CD25^+^CD127^−^ which was linked to the probability of recurrence of the cancer in 2 patients \[[@CR63]\]. Another clinical study reported significantly higher cytokines (TNFα and IFN-y) levels, increased T cell response to autologous tumour tissue (IFN-y ELISPOT assay) after 4 weeks and higher cytotoxic activity of T cells after 4 and 8 weeks (measured by luciferase assay) after cryoablation in 20 high-risk prostate patients \[[@CR64]\]. In patients with metastatic hormone refractory prostate cancer, a combination of cryoablation and GM-CSF showed a 70% decrease of PSA levels and a median time to progression of 18 months. No correlation was seen between the increase tumour-specific T cell responses in the peripheral blood and the increased cytolytic activity (measured by luciferase assay) after 4 and 8 weeks \[[@CR65]\]. The addition of cryoablation to androgen deprivation therapy (ADT) in 30 prostate cancer patients with bone metastases significantly improved progression-free, cancer-specific and overall survival compared to 30 prostate patients only treated with ADT \[[@CR66]\].

No clinical trials have been performed so far to evaluate a combination of anti-CTLA-4 antibodies with cryoablation therapy in humans. Only immunotherapy with GM-CSF has been investigated. Currently, a phase II trial of the combination of pembrolizumab and cryosurgery in stage IV prostate patients is ongoing. In addition, other trials are ongoing searching for the relation between cryoablation and the effect on the immune system \[[@CR67]--[@CR70]\].

Lung cancer {#Sec9}
-----------

Percutaneous local ablative therapies are considered viable options for the treatment of stage IA non-small-cell lung carcinoma (NSCLC). Recurrent lesions after radiation therapy or surgery and metastatic lesions can be treated by means of ablation as well \[[@CR71], [@CR72]\].

Cryoablation of lung lesions is associated with lower pain levels and fewer complications in tumours located close to the chest wall and mediastinum or central lesions close to the hilum; however, no clinical randomised studies have been executed comparing the different percutaneous ablative therapies \[[@CR73], [@CR74]\].

NSCLC is a heterogeneous group of cancers which is known for high numbers of tumour-specific mutations that are linked with response to immunotherapy \[[@CR75]\]. In recent years, several immunotherapies have been approved for the treatment of lung cancer, namely PD-1 checkpoint inhibitors nivolumab and pembrolizumab and the anti-CTLA-4 inhibitor ipilimumab.

Preclinical work in a mouse model revealed that Intratumoural injection of DCs with cryoablation elicits a Th1 response with higher levels of IFN-y and effector memory CD8+ T cells observed from spleen cells resulting in protection against secondary tumours and prolonged survival \[[@CR76]\]. In another study, the addition of CpG ODN to the cryoablation plus DCs resulted in a significant reduction of new tumour growth, fewer metastasis development and a prolonged survival compared to all the therapies alone. A decrease in Tregs and increase in cytotoxic T cells were observed and linked to the better response in the combination group \[[@CR77]\]. In another study, the same treatment combination showed a higher elevation of CD4+ and CD8+ T cells and IL-12, IFN-y and TNFα together with a delay in tumour growth and improved survival in mice treated with the combination therapy \[[@CR78]\]. Takahashi et al. reported the greatest immune response (higher numbers of specific T cells and higher levels of stimulating cytokines) and the slowest tumour growth after two cycles of cryoablation compared to one or three cycles of cryoablation \[[@CR79]\].

Clinical work combining cryoablation and allogenic intravenous NK cells showed an improvement in the quality of life and tumour response rates compared to cryoablation alone. Additional phase II/III trials must be conducted to reveal the potential benefits in larger patient groups before combination treatment is considered an alternative \[[@CR80]\]. Another strategy, consisting of a combination of cryoablation with gefitinib, an inhibitor of epidermal growth factor receptor's (EGFR) tyrosine kinase domain, showed significant improvement of overall response with a higher 1-year survival rate in patients treated with gefitinib and cryoablation compared to gefitinib alone \[[@CR81]\]. Lastly, 166 metastatic NSCLC patients received either cryoablation alone, cryoablation followed by immunotherapy (DC-CIK) or chemotherapy or all three therapies. The survival of patients treated with cryoablation combined with chemo or immunotherapy was longer than treatment consisting of chemo or immunotherapy alone (18 and 17 months vs 8.5 and 12 months). The overall survival in patients that received the triple combination therapy (cryoablation, immunotherapy and chemotherapy) was significantly longer (27 months) compared to other groups \[[@CR82]\].

These studies show positive results for the combination of cryoablation and stimulants to the immune system, NK cell therapy or DC-CIK, with improvement in survival. Clinical results are expected from a phase II study where cryoablation is combined with an immune checkpoint inhibitor \[[@CR83], [@CR84]\].

Melanoma {#Sec10}
--------

Cryoablation is used for the treatment of benign superficial lesions, such as actinic keratosis, but it is not indicated as a treatment for primary melanoma. Only in unresectable lesions with high metastatic load, cryoablation may diminish tumour load by ablation of the primary site \[[@CR85], [@CR86]\]. The treatment of melanoma metastasis can be performed with cryoablation to slow down the rate of tumour spread \[[@CR87], [@CR88]\]. In metastatic mouse models, combinations with different immunostimulants (including TLR 9 and CPG) have shown an enhanced effect of cryoablation for suppression of new tumour growth \[[@CR26], [@CR89]--[@CR91]\]. A pilot study observed the induction of endogenous heat-shock protein after administration of GM-CSF and radiofrequency ablation or cryoablation in metastatic melanoma patients, with a small number of subjects demonstrating the combination therapy as a feasible and safe therapeutic option \[[@CR92]\]. The combination of cryoablation and immunotherapy may be beneficial in the metastatic stetting to overcome the limitations of the immunotherapy. Currently, two trials are open combining immunotherapy and cryoablation (Table [3](#Tab3){ref-type="table"}).

Conclusion {#Sec11}
==========

Cryoablation has proven to be successful for local control in various cancer types. Mostly, it is indicated for tumours at an early stage or those not eligible for surgery. The synergies of local ablative techniques together with systemic treatments are currently one of the most exciting developments of interventional oncology. Particularly, given that cryoablation provides a pool of antigens visible for the immune system to induce an immune-specific activation directed against the tumour cells. In this review, a total of 41 out of 45 publications show favourable effects for cryoablation when combined with other therapies, potentially enhancing the anti-cancer immune response. This emphasises the potential advantage of this ablation technique as an adjunct with immunotherapy.

RCC and NSCLC are the neoplasms where cryoablation and its synergy with immunotherapy are predominantly studied. Both, immunostimulants for the innate and adaptive immune system demonstrate feasibility and effectiveness. For the translation of the results seen in animals and small groups of patients, larger prospective trials need to be designed to first study safety and efficacy before moving into randomized controlled settings. In the next 5 years, several pilot, phase I and early II clinical trials currently in place will demonstrate whether or not the combination of cryoablation and the immune system will have a true beneficial effect. This benefit can come from two different approaches that is first the contribution of cryoablation to immunological systemic effect of immunotherapy. Second, the impact of immunotherapy to overcome the limitations of cryoablation related to the upregulation of PD-L1. The features of imaging and molecular biomarkers, such as PD-L1 and others will help to optimise the combination strategies.

Furthermore, the strategy of combining cryoablation with new therapeutic options (specifically DC vaccine, CAR T cells, oncolytic viruses and adoptive T cell transfer) will provide a broader scale of immune-boosting therapies that will hopefully translate into the clinics and may thereby provide even better outcomes when combined with cryoablation.
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